Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].

× No keyword cloud information.

24 in total

1. Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Authors: Katherine S Panageas; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán Urgoiti; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M Deangelis; Suresh C Jhanwar; Marc K Rosenblum; Andrew B Lassman
Journal: Neuro Oncol Date: 2012-05-31 Impact factor: 12.300

2. Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.

Authors: Tosol Yu; Hyun-Cheol Kang; Do Hoon Lim; Il Han Kim; Woong-Ki Chung; Chang-Ok Suh; Byung Ock Choi; Kwan Ho Cho; Jae Ho Cho; Jin Hee Kim; Chul-Kee Park; Yong-Kil Hong; In Ah Kim
Journal: J Neurooncol Date: 2014-11-13 Impact factor: 4.130

3. Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma.

Authors: Patrick G Morris; Andrew B Lassman
Journal: Nat Rev Clin Oncol Date: 2010-08 Impact factor: 66.675

4. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.

Authors: Y Y Wang; K Wang; S W Li; J F Wang; J Ma; T Jiang; J P Dai
Journal: AJNR Am J Neuroradiol Date: 2015-08-27 Impact factor: 3.825

5. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).

Authors: Silvia Scoccianti; Stefano Maria Magrini; Umberto Ricardi; Beatrice Detti; Marco Krengli; Salvatore Parisi; Filippo Bertoni; Guido Sotti; Samantha Cipressi; Vincenzo Tombolini; Stefano Dall'oglio; Marco Lioce; Calogero Saieva; Michela Buglione; Cristina Mantovani; Giovanni Rubino; Paolo Muto; Vincenzo Fusco; Laura Fariselli; Costantino de Renzis; Laura Masini; Riccardo Santoni; Luigi Pirtoli; Giampaolo Biti
Journal: Neuro Oncol Date: 2012-04-25 Impact factor: 12.300

6. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors: Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal: Neuro Oncol Date: 2011-06 Impact factor: 12.300

Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].

1. Initial treatment patterns over time for anaplastic oligodendroglial tumors.

2. Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.

3. Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma.

4. Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.

5. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).

6. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

7. Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

8. Case presentation - A five-year survival of the patient with glioblastoma brain tumor.

9. Success at last: a molecular factor that informs treatment.

Review 10. The emerging role of galectins in high-fatality cancers.